Cationic Lipid Chimeras for Inner Ear Protein Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current protein delivery methods face challenges in efficiently and specifically delivering proteins to mammalian cells, particularly for intracellular targets, due to rapid degradation, neutralization by serum proteins, and low endosomal escape efficiency, which limits their therapeutic and research applications.
Innovation Solution
The use of cationic lipid formulations encapsulating chimeric molecules comprising proteins or peptides fused with anionic molecules, such as supercharged proteins or oligonucleotides, to facilitate efficient and specific delivery to cells like hair cells and supporting cells in the inner ear, leveraging membrane destabilization and electrostatic interactions for enhanced uptake and endosomal escape.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional protein delivery methods are used, then proteins can be delivered to cells, but the proteins are rapidly degraded and neutralized by serum proteins, resulting in low delivery efficiency
Solution Approach 1:
The patent uses cationic lipids as intermediary carriers to deliver proteins. The lipids form complexes with the proteins, protecting them from degradation and neutralization by serum proteins during transport to the cell surface, thereby improving delivery efficiency and stability
Solution Approach 2:
The invention creates composite structures by fusing proteins with cationic lipid molecules. This composite approach combines the benefits of protein functionality with the protective and membrane-interacting properties of cationic lipids, enhancing both stability and delivery efficiency
2Ease of operation
If cationic protein-based delivery methods are used, then endocytosis is facilitated, but endosomal escape efficiency remains low and lysosomal degradation occurs
Solution Approach 1:
The patent modifies the charge parameters of the delivery system by using cationic lipids with specific charge densities. This parameter change enables the complex to interact with and disrupt endosomal membranes, improving escape efficiency while maintaining ease of endocytosis
Solution Approach 2:
Instead of relying solely on natural endosomal escape mechanisms, the invention inverts the approach by using cationic lipids that actively disrupt endosomal membranes from the inside, reversing the typical passive escape pathway and achieving higher escape efficiency
3Adaptability or versatility
If DNA delivery methods are used, then intracellular targets can be accessed, but permanent recombination into the genome and disruption of endogenous genes occur
Solution Approach 1:
The patent extracts the intracellular target access function from DNA-based methods and implements it through direct protein delivery. By delivering the functional protein directly rather than its encoding DNA, the method achieves intracellular target access without the risk of genomic integration
Solution Approach 2:
The invention uses transient protein molecules that perform their function and are then degraded, replacing the need for permanent DNA integration. These short-lived protein carriers provide the necessary intracellular activity without creating permanent genetic changes
4Object-affected harmful factors
If mRNA delivery is used, then nuclear transport is avoided and genomic insertion risk is reduced, but immunogenicity and RNA stability issues persist
Solution Approach 1:
Instead of delivering the genetic blueprint (mRNA or DNA), the patent delivers the functional copy directly in the form of proteins. This copying approach bypasses the need for nuclear transport and eliminates genomic insertion risks while avoiding the stability and immunogenicity issues of RNA
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables high-efficiency delivery of therapeutic proteins and gene editing agents directly to target cells within the inner ear, effectively correcting genetic mutations associated with deafness, with improved stability and reduced immune response, thereby restoring hearing function.
Implementation Method 1
The use of cationic lipid formulations encapsulating chimeric molecules comprising proteins or peptides fused with anionic molecules, such as supercharged proteins or oligonucleotides, to facilitate efficient and specific delivery to cells
Implementation Method 2
leveraging membrane destabilization and electrostatic interactions for enhanced uptake and endosomal escape
Data Source
AI summary
Compositions are described for direct protein delivery into multiple cell types in the mammalian inner ear. The compositions are used to deliver protein(s) (such as gene editing factors) editing of genetic mutations associated with deafness or associated disorders thereof. The delivery of genome editing proteins for gene editing and correction of genetic mutations protect or restore hearing from genetic deafness. Methods of treatment include the intracellular delivery of these molecules to a specific therapeutic target.